Blood-based protein profiling identifies serum protein c-KIT as a novel biomarker for hypertrophic cardiomyopathy
Kristina Sonnenschein1,2, Jan Fiedler1, David de Gonzalo-Calvo1,3,4
1Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany.
Insights
We identified c-KIT as a novel biomarker for hypertrophic cardiomyopathy (HCM). Serum c-KIT levels were lower in HCM patients, while cardiac tissue showed higher levels, suggesting its role in fibrosis.
Area of Science:
- Cardiology
- Biochemistry
- Genetics
Background:
- Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with obstructive (HOCM) and non-obstructive (HNCM) forms.
- HCM is characterized by cardiomyocyte hypertrophy and cardiac fibrosis, increasing sudden cardiac death risk.
- Identifying reliable biomarkers for HCM is crucial for diagnosis and understanding disease mechanisms.
Purpose of the Study:
- To investigate protein biomarkers for differentiating hypertrophic cardiomyopathy (HCM) patients from healthy individuals.
- To identify proteins associated with cardiometabolic processes in HCM.
- To explore the potential of c-KIT as a novel biomarker for HCM.
Main Methods:
- Protein screening using proximity extension assay technology on 92 cardiometabolic proteins.
- Quantitative measurement of candidate proteins in a cohort of 60 HCM patients and 28 healthy controls.
- Validation of potential biomarkers, including c-KIT, in serum and cardiac tissue.
Main Results:
- c-KIT was the only significantly regulated protein differentiating HCM patients from controls.
- Serum c-KIT levels were significantly lower in HCM patients compared to healthy controls, even after adjustment.
- Cardiac tissue from HOCM patients showed significantly higher c-KIT levels, correlating with fibrotic myocardium.
Conclusions:
- c-KIT is a promising novel biomarker for distinguishing HCM patients from the healthy population.
- Lower serum c-KIT may indicate disease presence, while higher cardiac tissue levels suggest a role in fibrosis.
- Further research into c-KIT's functional role in HOCM fibrosis is warranted.
Abstract:
Hypertrophic cardiomyopathy (HCM) is one of the most common hereditary heart diseases and can be classified into an obstructive (HOCM) and non-obstructive (HNCM) form. Major characteristics for HCM are the hypertrophy of cardiomyocytes and development of cardiac fibrosis. Patients with HCM have a higher risk for sudden cardiac death compared to a healthy population. In the present study, we investigated the abundancy of selected proteins as potential biomarkers in patients with HCM. We included 60 patients with HCM and 28 healthy controls and quantitatively measured the rate of a set of 92 proteins already known to be associated with cardiometabolic processes via protein screening using the proximity extension assay technology in a subgroup of these patients (20 HCM and 10 healthy controls). After validation of four hits in the whole cohort of patients consisting of 88 individuals (60 HCM patients, 28 healthy controls) we found only one candidate, c-KIT, which was regulated significantly different between HCM patients and healthy controls and thus was chosen for further analyses. c-KIT is a tyrosine-protein kinase acting as receptor for the stem cell factor and activating several pathways essential for cell proliferation and survival, hematopoiesis, gametogenesis and melanogenesis. Serum protein levels of c-KIT were significantly lower in patients with HCM than in healthy controls, even after adjusting for confounding factors age and sex. In addition, c-KIT levels in human cardiac tissue of patients with HOCM were significant higher compared to controls indicating high levels of c-KIT in fibrotic myocardium. Furthermore, c-KIT concentration in serum significantly correlated with left ventricular end-diastolic diameter in HOCM, but not HCM patients. The present data suggest c-KIT as a novel biomarker differentiating between patients with HCM and healthy population and might provide further functional insights into fibrosis-related processes of HOCM.
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification


